Gedeon Richter Plc.
http://www.richter.hu
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gedeon Richter Plc.
Richter Heralds Xarelto Opportunity As Proof Generics Still Have Life
Hungarian leader Gedeon Richter spoke at length of its recent European roll-out of generic competition to Bayer’s Xarelto blockbuster, while also providing key updates for its biosimilar pipeline, as the firm reported financial first-half results.
Strides Expects Bhami Tech To Boost CDMO Arm; Former CFO Now MD And Group CEO
Strides expects a licensing of Bhami’s formulation technology that enables subcutaneous delivery of biologics to boost associate company OneSource’s CDMO business. Meanwhile, its former CFO has been appointed MD and group CEO amid a US portfolio re-balance
Gedeon Richter Is Latest To File European Denosumab
Gedeon Richter has revealed that its European filing for a denosumab biosimilar rival to Prolia/Xgeva has been accepted for review by the EMA.
Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs
The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- PregLem Holding SA
- Richter Gedeon Vegyeszeti Gyar Nyrt
- Richter-Helm BioTec GmbH
- FINOX Biotech
- Finox AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice